Sign in
Not yet recruitingPhase 2

Sevoflurane Sedation in Patients With Septic Shock

Key facts

Who runs it
University of Zurich
Where
Switzerland4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
153 people, planned
Started
Jan 2026
Expected to end
Nov 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sevoflurane
  • Control Group
Record updated
1 April 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Male and female patients, age 18 to 80 years
  • Intensive care Unit (ICU) patients with septic shock (despite fluid resuscitation vasopressors needed to maintain mean arterial pressure ≥65 millimeter of mercury (mmHg), and serum lactate >2mmol/l even with fluid application)
  • Treatment of septic shock on ICU with vasopressors not longer than 12 hours
  • Sedation and mechanical ventilation on ICU
  • Female patients of childbearing potential with negative pregnancy test
  • Informed Consent as documented by signature

Who cannot take part

  • Previous surgery and/or anesthesia (within last 7 days)
  • Systemic corticosteroids in the phase before hospitalization (> 10mg/d prednisone)
  • Significant concomitant disease (acute cerebral vascular event, acute coronary syndrome, decompensated heart failure, acute pulmonary edema, major cardiac arrhythmia, seizure, burn, chronic kidney disease, end stage liver failure, neuromuscular disease)
  • Organ transplant
  • Subject with active malignancy receiving
  • chemotherapy or radiation treatment within last 60 days
  • Anti-tumor necrosis factor (TNF) therapy
  • Enrollment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion
  • Suspected or known intolerance by history to volatile anesthetics (malignant hyperthermia)
  • Autoimmune disease
  • Hepatitis B/C virus infection
  • Application of nitric oxide (NO)
  • Immunosuppressive agents
  • AIDS
  • Pregnancy and/or Breast feeding
  • Use of cytokine absorber

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.

Read full original descriptionShow less

Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.

The 2 groups in the trial

  • Sevoflurane SedationTreatment being tested

    Patients randomized into experimental group will be treated with sevoflurane during 4 hours

    Treatment: Sevoflurane

  • Propofol SedationExisting treatment, for comparison

    Patients randomized into Control Group will get continued intravenous sedation with propofol

    Treatment: Control Group

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock
Fit questions
Built from NCT03643367, who can take part
Record updated
1 April 2025